326 related articles for article (PubMed ID: 25311111)
1. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
Chai X; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Tung N; Weitzel JN; Couch FJ; Hulick PJ; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Blum JL; Domchek SM; Chen J; Rebbeck TR
Breast Cancer Res Treat; 2014 Nov; 148(2):397-406. PubMed ID: 25311111
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
[TBL] [Abstract][Full Text] [Related]
3. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP
Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
[TBL] [Abstract][Full Text] [Related]
4. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
[TBL] [Abstract][Full Text] [Related]
5. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
Stjepanovic N; Villacampa G; Nead KT; Torres-Esquius S; Melis GG; Nathanson KL; Teule A; Brunet J; Y Cajal TR; Llort G; Dienstmann R; Rue M; Domchek SM; Balmaña J
Eur J Cancer; 2020 Jun; 132():53-60. PubMed ID: 32325420
[TBL] [Abstract][Full Text] [Related]
6. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY
J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354
[TBL] [Abstract][Full Text] [Related]
7. Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: Are there factors associated with the choice?
Manoukian S; Alfieri S; Bianchi E; Peissel B; Azzollini J; Borreani C
Psychooncology; 2019 Sep; 28(9):1871-1878. PubMed ID: 31264307
[TBL] [Abstract][Full Text] [Related]
8. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
Choi YH; Terry MB; Daly MB; MacInnis RJ; Hopper JL; Colonna S; Buys SS; Andrulis IL; John EM; Kurian AW; Briollais L
JAMA Oncol; 2021 Apr; 7(4):585-592. PubMed ID: 33630024
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation.
Kim D; Kang E; Hwang E; Sun Y; Hwang Y; Yom CK; Kim K; No JH; Kim YB; Kim SW
Fam Cancer; 2013 Dec; 12(4):621-8. PubMed ID: 23504064
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
[TBL] [Abstract][Full Text] [Related]
11. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
Mavaddat N; Antoniou AC; Mooij TM; Hooning MJ; Heemskerk-Gerritsen BA; ; Noguès C; Gauthier-Villars M; Caron O; Gesta P; Pujol P; Lortholary A; ; Barrowdale D; Frost D; Evans DG; Izatt L; Adlard J; Eeles R; Brewer C; Tischkowitz M; Henderson A; Cook J; Eccles D; ; van Engelen K; Mourits MJE; Ausems MGEM; Koppert LB; Hopper JL; John EM; Chung WK; Andrulis IL; Daly MB; Buys SS; ; Benitez J; Caldes T; Jakubowska A; Simard J; Singer CF; Tan Y; Olah E; Navratilova M; Foretova L; Gerdes AM; Roos-Blom MJ; Van Leeuwen FE; Arver B; Olsson H; Schmutzler RK; Engel C; Kast K; Phillips KA; Terry MB; Milne RL; Goldgar DE; Rookus MA; Andrieu N; Easton DF; ; ;
Breast Cancer Res; 2020 Jan; 22(1):8. PubMed ID: 31948486
[TBL] [Abstract][Full Text] [Related]
12. Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis.
Wang Y; Song Z; Zhang S; Wang X; Li P
Eur J Surg Oncol; 2022 Jun; 48(6):1209-1216. PubMed ID: 35216860
[TBL] [Abstract][Full Text] [Related]
13. Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy.
Cohen JV; Chiel L; Boghossian L; Jones M; Stopfer JE; Powers J; Rebbeck TR; Nathanson KL; Domchek SM
Fam Cancer; 2012 Mar; 11(1):69-75. PubMed ID: 21898151
[TBL] [Abstract][Full Text] [Related]
14. Uptake and efficacy of bilateral risk reducing surgery in unaffected female
Marcinkute R; Woodward ER; Gandhi A; Howell S; Crosbie EJ; Wissely J; Harvey J; Highton L; Murphy J; Holland C; Edmondson R; Clayton R; Barr L; Harkness EF; Howell A; Lalloo F; Evans DG
J Med Genet; 2022 Feb; 59(2):133-140. PubMed ID: 33568438
[TBL] [Abstract][Full Text] [Related]
15. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
Domchek SM; Friebel TM; Garber JE; Isaacs C; Matloff E; Eeles R; Evans DG; Rubinstein W; Singer CF; Rubin S; Lynch HT; Daly MB; Weitzel J; Ganz PA; Pichert G; Olopade OI; Tomlinson G; Tung N; Blum JL; Couch F; Rebbeck TR
Breast Cancer Res Treat; 2010 Nov; 124(1):195-203. PubMed ID: 20180014
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
Rebbeck TR; Kauff ND; Domchek SM
J Natl Cancer Inst; 2009 Jan; 101(2):80-7. PubMed ID: 19141781
[TBL] [Abstract][Full Text] [Related]
17. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Kauff ND; Domchek SM; Friebel TM; Robson ME; Lee J; Garber JE; Isaacs C; Evans DG; Lynch H; Eeles RA; Neuhausen SL; Daly MB; Matloff E; Blum JL; Sabbatini P; Barakat RR; Hudis C; Norton L; Offit K; Rebbeck TR
J Clin Oncol; 2008 Mar; 26(8):1331-7. PubMed ID: 18268356
[TBL] [Abstract][Full Text] [Related]
18. Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
Solsky I; Chen J; Rebbeck TR
Gynecol Oncol; 2020 Feb; 156(2):363-376. PubMed ID: 31918993
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.
Schwartz MD; Isaacs C; Graves KD; Poggi E; Peshkin BN; Gell C; Finch C; Kelly S; Taylor KL; Perley L
Cancer; 2012 Jan; 118(2):510-7. PubMed ID: 21717445
[TBL] [Abstract][Full Text] [Related]
20. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.
Beattie MS; Crawford B; Lin F; Vittinghoff E; Ziegler J
Genet Test Mol Biomarkers; 2009 Feb; 13(1):51-6. PubMed ID: 19309274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
